Generex Biotechnology of Toronto says results of a Mayo Clinic study bolster the evidence for a cancer vaccine developed by Worcester subsidiary Antigen Express Inc.
The mouse-model study, published in the peer-reviewed Journal of Immunology, found that Antigen Express technology was able to activate helpful immune-boosting cells without activating cells that suppress immune response.
The breast cancer vaccine developed using the technology is now in a phase-two clinical trial.
